TARGET
saveIL-23
Interleukin-23; psoriasis and IBD target.
also known as: il23, interleukin-23
drugs
0
catalysts
0
news
40
companies
0
Top drugs
no drugs tagged with this interest yet
🐶 Top companies
no companies tagged with this interest yet
Recent catalysts
no catalysts tagged with this interest yet
Recent news
view all →- AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trialendpoints · 1h ago
- AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trialfiercebiotech · 8h ago
- 6 immunology targets to sustain a mammoth I&I marketbiospace · 21d ago
- 5 biotechs braving the commercial waters with product launchesbiospace · 1mo ago
- Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 winsfiercebiotech · 1mo ago
- Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPOfiercebiotech · 2mo ago
- Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trialsfiercebiotech · 2mo ago
- InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis testfiercebiotech · 2mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that